Diabetes
Before prescribing fluconazole for diabetic patients, consider these drug interactions and CDC Guidelines2,9-13
For women on certain antidiabetic drugs, fluconazole may increase the risk of serious hypoglycemic episodes.11,12
Fluconazole can interact with sulfonylureas (commonly used oral hypoglycemic drugs), which can increase drug plasma levels and lead to clinically dangerous episodes of hypoglycemia11-13
In a recent survey, 73% of OB/GYNs said they recommend fluconazole for vaginal yeast infection in women with diabetes more than butoconazole, miconazole, or terconazole.15 .
The prevalence of non-albicans species and potential drug interactions may warrant closer attention to VVC in patients with diabetes.
For women with diabetes, vaginal yeast infections are more likely to be caused by a non-albicans species.2,9,10
- For non-albicans VVC, CDC Guidelines suggest a longer duration of therapy (7-14 days) with a non-fluconazole azole regimen as first-line therapy2
- Miconazole, the active ingredient in MONISTAT®, treats C. glabrata—the most prevalent non-albicans species—while prescription azoles do not.16
MONISTAT® 7 meets the CDC Guidelines for treating non-albicans VVC.
In a recent survey, 73% of OB/GYNs said they recommend fluconazole for vaginal yeast infection in women with diabetes more than butoconazole, miconazole, or terconazole.15 The prevalence of non-albicans species and potential drug interactions may warrant closer attention to VVC in patients with diabetes.
For vaginal yeast infection in patients with diabetes, recommend MONISTAT® 7 .
